1. Дедов И.И., Петеркова В.А. Руководство по детской эндокринологии. Москва: Универсум Паблишинг, 2006. 600 p. 2. Charmandari E., Nicolaides N.C., Chrousos G.P. Adrenal insufficiency // The Lancet. 2014. Vol. 383, № 9935. P. 2152–2167. 3. Kirkgoz T., Guran T. Primary adrenal insufficiency in children: Diagnosis and management // Best Pract. Res. Clin. Endocrinol. Metab. 2018. Vol. 32, № 4. P. 397–424. 4. Park J., Didi M., Blair J. The diagnosis and treatment of adrenal insufficiency during childhood and adolescence // Arch. Dis. Child. 2016. Vol. 101, № 9. P. 860–865. 5. Ventura M. et al. The spectrum of pediatric adrenal insufficiency: insights from 34 years of experience // J. Pediatr. Endocrinol. Metab. 2019. Vol. 32, № 7. P. 721–726. 6. Oelkers W. Adrenal Insufficiency // N. Engl. J. Med. 1996. Vol. 335, № 16. P. 1206–1212. 7. Oelkers W., Diederich S., Bähr V. Diagnosis and therapy surveillance in Addison’s disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. // J. Clin. Endocrinol. Metab. 1992. Vol. 75, № 1. P. 259–264. 8. Jones D.A., Miras A., Tringham J.R. Addison’s disease: a diagnostic challenge // Br. J. Hosp. Med. 2008. Vol. 69, № Sup12. P. 192–195. 9. Bleicken B. et al. Delayed Diagnosis of Adrenal Insufficiency Is Common: A Cross-Sectional Study in 216 Patients // Am. J. Med. Sci. 2010. Vol. 339, № 6. P. 525–531. 10. White P.C., Speiser P.W. Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency* // Endocr. Rev. 2000. Vol. 21, № 3. P. 245–291. 11. Rushworth R.L., Torpy D.J., Falhammar H. Adrenal crises: perspectives and research directions // Endocrine. 2017. Vol. 55, № 2. P. 336–345. 12. Bornstein S.R. et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline // J. Clin. Endocrinol. Metab. 2016. Vol. 101, № 2. P. 364– 389. 13. Chakera A.J., Vaidya B. Addison Disease in Adults: Diagnosis and Management // Am. J. Med. 2010. Vol. 123, № 5. P. 409–413. 14. Erturk E., Jaffe C.A., Barkan A.L. Evaluation of the Integrity of the Hypothalamic-PituitaryAdrenal Axis by Insulin Hypoglycemia Test 1 // J. Clin. Endocrinol. Metab. 1998. Vol. 83, № 7. P. 2350–2354. 15. El-Farhan N. et al. Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays // Clin. Endocrinol. (Oxf.). 2013. Vol. 78, № 5. P. 673–680. 16. Deutschbein T. et al. Diagnosis of secondary adrenal insufficiency in patients with hypothalamic–pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test // Eur. J. Endocrinol. 2009. Vol. 160, № 1. P. 9–16. 17. Schmidt I.L. et al. Diagnosis of Adrenal Insufficiency: Evaluation of the CorticotropinReleasing Hormone Test and Basal Serum Cortisol in Comparison to the Insulin Tolerance Test in Patients with Hypothalamic-Pituitary-Adrenal Disease // J. Clin. Endocrinol. Metab. 2003. Vol. 88, № 9. P. 4193–4198. 18. Kazlauskaite R. et al. Corticotropin Tests for Hypothalamic-Pituitary- Adrenal Insufficiency: A Metaanalysis // J. Clin. Endocrinol. Metab. 2008. Vol. 93, № 11. P. 4245–4253. 19. Pecori Giraldi F. et al. Assessment of ACTH assay variability: a multicenter study // Eur. J. Endocrinol. 2011. Vol. 164, № 4. P. 505–512. 20. Van Rijn J.L.M.L. et al. Evaluation of ACTH immunoradiometric assays // Clin. Biochem. 1996. Vol. 29, № 1. P. 93–95. 32 21. Baker P.R. et al. Haplotype Analysis Discriminates Genetic Risk for DR3-Associated Endocrine Autoimmunity and Helps Define Extreme Risk for Addison’s Disease // J. Clin. Endocrinol. Metab. 2010. Vol. 95, № 10. P. E263–E270. 22. Hägg E., Asplund K., Lithner F. VALUE OF BASAL PLASMA CORTISOL ASSAYS IN THE ASSESSMENT OF PITUITARY-ADRENAL INSUFFICIENCY // Clin. Endocrinol. (Oxf.). 1987. Vol. 26, № 2. P. 221–226. 23. Jenkins D. et al. Use of ACTH in the diagnosis of adrenal cortical insufficiency // Am. J. Med. 1955. Vol. 18, № 1. P. 3–14. 24. Oelkers W. et al. Dose-Response Relationships Between Plasma Adrenocorticotropin (ACTH), Cortisol, Aldosterone, and 18-Hydroxycorticosterone After Injection of ACTH-(1–39) or Human Corticotropin-Releasing Hormone in Man* // J. Clin. Endocrinol. Metab. 1988. Vol. 66, № 1. P. 181–186. 25. Lee M.K.V. et al. Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study // Postgrad. Med. J. 2013. Vol. 89, № 1057. P. 617–620. 26. Klose M. et al. Factors Influencing the Adrenocorticotropin Test: Role of Contemporary Cortisol Assays, Body Composition, and Oral Contraceptive Agents // J. Clin. Endocrinol. Metab. 2007. Vol. 92, № 4. P. 1326–1333. 27. Magnotti M., Shimshi M. Diagnosing Adrenal Insufficiency: Which Test is Best—The 1-μG or the 250-μG Cosyntropin Stimulation Test? // Endocr. Pract. 2008. Vol. 14, № 2. P. 233–238. 28. May M.E., Carey R.M. Rapid adrenocorticotropic hormone test in practice. Retrospective review // Am. J. Med. 1985. Vol. 79, № 6. P. 679–684. 29. Oelkers W. The role of high- and low-dose corticotropin tests in the diagnosis of secondary adrenal insufficiency // Eur. J. Endocrinol. 1998. Vol. 139, № 6. P. 567–570. 30. Pura M. et al. The low-dose (1 μg) Cosyntropin Test (LDT) for Primary Adrenocortical Insufficiency: Defining the Normal Cortisol Response and Report on First Patients with Addison Disease Confirmed with LDT // Exp. Clin. Endocrinol. Diabetes. 2009. Vol. 118, № 03. P. 151–157. 31. Saenger P. et al. Progressive Adrenal Failure in Polyglandular Autoimmune Disease* // J. Clin. Endocrinol. Metab. 1982. Vol. 54, № 4. P. 863–868. 32. Coco G. et al. Estimated Risk for Developing Autoimmune Addison’s Disease in Patients with Adrenal Cortex Autoantibodies // J. Clin. Endocrinol. Metab. 2006. Vol. 91, № 5. P. 1637– 1645. 33. De Bellis A. et al. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. // J. Clin. Endocrinol. Metab. 1993. Vol. 76, № 4. P. 1002–1007. 34. Betterle C. et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies // J. Endocrinol. 1988. Vol. 117, № 3. P. 467–475. 35. Conrad K. et al. Autoantibody diagnostics in clinical practice // Autoimmun. Rev. 2012. Vol. 11, № 3. P. 207–211. 36. Winqvist O., Karlsson F.A., Kämpe O. 21-hydroxylase, a major autoantigen in idiopathic Addison’s disease // The Lancet. 1992. Vol. 339, № 8809. P. 1559–1562. 37. Laureti S. et al. Etiological Diagnosis of Primary Adrenal Insufficiency Using an Original Flowchart of Immune and Biochemical Markers 1 // J. Clin. Endocrinol. Metab. 1998. Vol. 83, № 9. P. 3163–3168. 38. Speiser P.W. et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline // J. Clin. Endocrinol. Metab. 2010. Vol. 95, № 9. P. 4133–4160. 39. Bornstein S.R. Predisposing Factors for Adrenal Insufficiency // N. Engl. J. Med. 2009. Vol. 360, № 22. P. 2328–2339. 40. Vita J.A. et al. Clinical clues to the cause of Addison’s disease // Am. J. Med. 1985. Vol. 78, № 3. P. 461–466. 41. Horn M.A. et al. Screening for X-linked adrenoleukodystrophy among adult men with Addison’s disease // Clin. Endocrinol. (Oxf.). 2013. Vol. 79, № 3. P. 316–320. 33 42. Laureti S. et al. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison’s disease in young adult male patients. // J. Clin. Endocrinol. Metab. 1996. Vol. 81, № 2. P. 470– 474. 43. Purnell J.Q. et al. Association of 24-Hour Cortisol Production Rates, Cortisol-Binding Globulin, and Plasma-Free Cortisol Levels with Body Composition, Leptin Levels, and Aging in Adult Men and Women // J. Clin. Endocrinol. Metab. 2004. Vol. 89, № 1. P. 281–287. 44. Nickelsen T., Schulz F., Demisch K. Studies on Cortisol Substitution Therapy in Patients with Adrenal Insufficiency // Exp. Clin. Endocrinol. Diabetes. 2009. Vol. 82, № 04. P. 35–41. 45. Czock D. et al. Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids: // Clin. Pharmacokinet. 2005. Vol. 44, № 1. P. 61–98. 46. Plat L. et al. Metabolic Effects of Short-Term Elevations of Plasma Cortisol Are More Pronounced in the Evening Than in the Morning 1 // J. Clin. Endocrinol. Metab. 1999. Vol. 84, № 9. P. 3082–3092. 47. Simon N. et al. Pharmacokinetic Evidence for Suboptimal Treatment of Adrenal Insufficiency with Currently Available Hydrocortisone Tablets: // Clin. Pharmacokinet. 2010. Vol. 49, № 7. P. 455–463. 48. Peacey S.R. et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? // Clin. Endocrinol. (Oxf.). 1997. Vol. 46, № 3. P. 255–261. 49. Howlett T.A. An Assessment of Optimal Hydrocortisone Replacement Therapy // Clin. Endocrinol. (Oxf.). 1997. Vol. 46, № 3. P. 263–268. 50. Laureti S., Falorni A., Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses // J. Endocrinol. Invest. 2003. Vol. 26, № 11. P. 1071–1075. 51. Barbetta L. et al. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism // J. Endocrinol. Invest. 2005. Vol. 28, № 9. P. 632–637. 52. Ekman B. et al. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency // Clin. Endocrinol. (Oxf.). 2012. Vol. 77, № 1. P. 18–25. 53. Forss M. et al. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey // BMC Endocr. Disord. 2012. Vol. 12, № 1. P. 8. 54. Fariss B.L. et al. Comparison of Absorption of Cortisone Acetate and Hydrocortisone Hemisuccinate* // J. Clin. Endocrinol. Metab. 1978. Vol. 47, № 5. P. 1137–1140. 55. Filipsson H. et al. The Impact of Glucocorticoid Replacement Regimens on Metabolic Outcome and Comorbidity in Hypopituitary Patients // J. Clin. Endocrinol. Metab. 2006. Vol. 91, № 10. P. 3954–3961. 56. Wiegand S. et al. Reduced 11β-hydroxysteroid dehydrogenase type 1 activity in obese boys // Eur. J. Endocrinol. 2007. Vol. 157, № 3. P. 319–324. 57. Bonfig W. et al. Hydrocortisone Dosing during Puberty in Patients with Classical Congenital Adrenal Hyperplasia: An Evidence-Based Recommendation // J. Clin. Endocrinol. Metab. 2009. Vol. 94, № 10. P. 3882–3888. 58. Grigorescu-Sido A. et al. Growth Analysis in Patients with 21-Hydroxylase Deficiency Influence of Glucocorticoid Dosage, Age at Diagnosis, Phenotype and Genotype on Growth and Height Outcome // Horm. Res. Paediatr. 2003. Vol. 60, № 2. P. 84–90. 59. Williams G.H. et al. Studies of the control of plasma aldosterone concentration in normal man // J. Clin. Invest. 1972. Vol. 51, № 7. P. 1731–1742. 60. Fiad T.M. et al. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency // Clin. Endocrinol. (Oxf.). 1996. Vol. 45, № 5. P. 529–534. 61. Keilholz U., Guthrie G.P. Case Report: Adverse Effect of Phenytoin on Mineralocorticoid Replacement with Fludrocortisone in Adrenal Insufficiency // Am. J. Med. Sci. 1986. Vol. 291, № 4. P. 280–283. 34 62. Ross I.L. et al. Cardiovascular Risk Factors in Patients with Addison’s Disease: A Comparative Study of South African and Swedish Patients // PLoS ONE / ed. Stover C.M. 2014. Vol. 9, № 3. P. e90768. 63. Inder W.J., Meyer C., Hunt P.J. Management of hypertension and heart failure in patients with Addison’s disease // Clin. Endocrinol. (Oxf.). 2015. Vol. 82, № 6. P. 789–792. 64. Esposito D., Pasquali D., Johannsson G. Primary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy // J. Clin. Endocrinol. Metab. 2018. Vol. 103, № 2. P. 376–387. 65. Repping-Wuts H.J.W.J. et al. A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis // Eur. J. Endocrinol. 2013. Vol. 169, № 1. P. 17–22. 66. Harsch I.A. et al. Cortisone replacement therapy in endocrine disorders - quality of self-care // J. Eval. Clin. Pract. 2010. 67. Braatvedt G.D., Newrick P.G., Corrall R.J. Patients’ self administration of hydrocortisone. // BMJ. 1990. Vol. 301, № 6764. P. 1312–1312. 68. Fleming L.K., Rapp C.G., Sloane R. Caregiver Knowledge and Self-Confidence of Stress Dosing of Hydrocortisone in Children With Congenital Adrenal Hyperplasia // J. Pediatr. Nurs. 2011. Vol. 26, № 6. P. e55–e60. 69. Quinkler M. et al. A European Emergency Card for adrenal insufficiency can save lives // Eur. J. Intern. Med. 2015. Vol. 26, № 1. P. 75–76. 70. Allolio B. EXTENSIVE EXPERTISE IN ENDOCRINOLOGY: Adrenal crisis // Eur. J. Endocrinol. 2015. Vol. 172, № 3. P. R115–R124. 71. White K., Arlt W. Adrenal crisis in treated Addison’s disease: a predictable but under-managed event // Eur. J. Endocrinol. 2010. Vol. 162, № 1. P. 115–120. 72. Hahner S. et al. High Incidence of Adrenal Crisis in Educated Patients With Chronic Adrenal Insufficiency: A Prospective Study // J. Clin. Endocrinol. Metab. 2015. Vol. 100, № 2. P. 407– 416. 73. Reisch N. et al. Frequency and causes of adrenal crises over lifetime in patients with 21- hydroxylase deficiency // Eur. J. Endocrinol. 2012. Vol. 167, № 1. P. 35–42. 74. Fonseca V. et al. Acute adrenal crisis precipitated by thyroxine. // BMJ. 1986. Vol. 292, № 6529. P. 1185–1186. 75. Erichsen M.M. et al. Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death // Eur. J. Endocrinol. 2009. Vol. 160, № 2. P. 233–237.